Grifols to acquire the remaining 56% stake in GigaGen for $80m.

Grifols, a global healthcare company, agreed to acquire the remaining 56% stake in GigaGen, a biotechnology company specialized in the early discovery and development of recombinant biotherapeutic medicines, for $80m. "We are further strengthening our innovation strategy by investing in solid projects, such as Alkahest and now GigaGen, with the aim of helping patients live longer and better lives. Projects like these support our long-term vision and have high potential to bolster our corporate growth and business fundamentals," Víctor Grífols Deu, Grifols Co-CEO.